Volume 93, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Seasonal malaria chemoprevention (SMC) is defined as the intermittent administration of full treatment courses of an antimalarial drug to children during the peak of malaria transmission season with the aim of preventing malaria-associated mortality and morbidity. SMC using sulfadoxine–pyrimethamine (SP) combined with amodiaquine (AQ) is a promising strategy to control malaria morbidity in areas of highly seasonal malaria transmission. However, a concern is whether SMC can delay the natural acquisition of immunity toward malaria parasites in areas with intense SMC delivery. To investigate this, total IgG antibody (Ab) responses to antigens glutamate-rich protein R0 (GLURP-R0) and apical membrane antigen 1 (AMA-1) were measured by enzyme-linked immunosorbent assay in Senegalese children under the age of 10 years in 2010 living in Saraya and Velingara districts (with SMC using SP + AQ [SMC+] since 2007) and Tambacounda district (without SMC (SMC−)). For both antigens, total IgG response were significantly higher in the SMC− compared with the SMC+ group (for GLURP-R0, < 0.001 and for AMA-1, = 0.001). There was as well a nonsignificant tendency for higher percentage of positive responders in the SMC− compared with the SMC+ group (for GLURP-R0: 22.2% versus 14.4%, respectively [ = 0.06]; for AMA-1: 45.6% versus 40.0%, respectively [ = 0.24]). Results suggest that long-term malaria chemoprevention by SMC/SP + AQ have limited impact on the development of acquired immunity, as tested using the antigens GLURP-R0 and AMA-1. However, other factors, not measured in this study, may interfere as well.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, Alonso P, , 2005. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365: 14811483.
  2. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C, , 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 15331542.
  3. ter Kuile FO, Van Eijk AM, Filler SJ, , 2007. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297: 26032616.
  4. World Health Organization, 2004. A Strategic Framework for Malaria Prevention and Control during Pregnancy in the African Region. Geneva, Switzerland: World Health Organization.
  5. Wilson AL, , 2011. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 6: e16976.
  6. WHO, 2012. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum Malaria Control in Highly Seasonal Transmission Areas of the Sahel Sub-Region in Africa. Geneva, Switzerland: World Health Organization.
  7. Cissé B, Sokhna C, Boulanger D, Milet J, el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF, , 2006. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double blind trial. Lancet 367: 659667.
  8. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B, , 2005. Cluster randomized trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727733.
  9. Ndiaye M, Tine R, Faye B, Ndiaye JL, Lo AC, Sylla K, Abiola A, Dieng Y, Ndiaye D, Hallett R, Gaye O, Alifrangis M, , 2013. Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal. Am J Trop Med Hyg 88: 11241129.
  10. Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, Ndiaye M, Sow D, De Sousa A, Gaye O, , 2011. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine–pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol Res 109: 133138.
  11. Hogh B, Petersen E, Crandall I, Gottschau A, Sherman IW, , 1994. Immune responses to band 3 neo antigens on Plasmodium falciparum-infected erythrocytes in subjects living in an area of intense malaria transmission are associated with low parasite density and high hematocrit value. Infect Immun 62: 43624366.
  12. Voller A, Wilson H, , 1964. Immunoligical aspects of a population under prophylaxis against malaria. BMJ 2: 551552.
  13. Quelhas D, Puyol L, Quinto L, Serra-Casas E, Nhampossa T, Macete E, Aide P, Mayor A, Mandomando I, Sanz S, Aponte JJ, Chauhan VS, Chitnis CE, Alonso PL, Menéndez C, Dobaño C, , 2008. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin Vaccine Immunol 15: 12821291.
  14. Schreiber N, Kobbe R, Adjei S, Adjei O, Klinkert MQ, May J, , 2007. Immune responses after single-dose sulphadoxine-pyrimethamine indicate underestimation of protective efficacy of intermittent preventive treatment in infants. Trop Med Int Health 12: 11571163.
  15. Dia I, Diop T, Rakotoarivony I, Kengne P, Fontenille D, , 2003. Bionomics of Anopheles gambiae Giles, An. arabiensis Patton, An. funestus Giles and An. nili (Theobald) (Diptera: Culicidae) and transmission of Plasmodium falciparum in a Sudano-Guinean zone (Ngari, Senegal). J Med Entomol 40: 279283.
  16. Corran PH, Cook J, Lynch C, Manjurano A, Cox J, Abeku T, Bousema T, Ghani AC, Drakeley C, Riley E, , 2008. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J 7: 195.
  17. Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, Noor AM, Snow RW, Drakeley C, , 2010. Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. Emerg Infect Dis 16: 392399.
  18. Cavanagh DR, Dobano C, Elhassan IM, Marsh K, Elhassan A, Hviid L, Khalil EATG, Theander TG, Arnot DE, McBride JS, , 2001. Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun 69: 12071211.
  19. Boulanger D, Sarr JB, Fillol F, Sokhna C, Cisse B, Schacht AM, Trape JF, Riveau G, Simondon F, Greenwood B, Remoué F, , 2010. Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children. Malar J 9: 363.

Data & Media loading...

  • Received : 16 Dec 2014
  • Accepted : 05 Jun 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error